Peptid-Klartext DE Community
Growth hormone

Sermorelin: Effects, Evidence and Risks

Research use only: Sermorelin is not approved as a medicine in Germany or the EU (approvals exist only in individual countries outside the EU). It is offered as a research substance labelled “for research purposes only – not for use in humans or animals”. This page summarises the state of research and is not a recommendation to use it.

Also known as Sermorelin, GHRH (1-29), Geref.

StatusApproved outside the EU only
EvidenceLarge studies
Drug classGHRH analogue (truncated growth hormone-releasing hormone) · injection
Add as vial in tracker

We only show doses for approved medicines according to the prescribing information – in the calculator.

What is Sermorelin?

Sermorelin consists of the first 29 amino acids of the body's own growth hormone-releasing hormone (GHRH). It stimulates the pituitary to release its own growth hormone.

How well studied is Sermorelin?

In the US, sermorelin (Geref) was approved for treating children with idiopathic GH deficiency and for testing GH reserve. There are no solid studies on anti-aging, muscle gain or fat loss in healthy people.

What side effects and risks does Sermorelin have?

Known effects include injection-site reactions, flushing and headache. Via GH/IGF-1, fluid retention and rising blood sugar are possible; stimulating GH is fundamentally problematic with active tumours. Grey-market and “anti-aging” products cannot be verified for purity or content.

Is Sermorelin approved in Germany?

In short: no – only outside the EU. US approval ended in 2008/2009 after the manufacturer withdrew it – according to the FDA not for safety or efficacy reasons. No sermorelin product is approved in the EU/Germany. Prohibited in sport (WADA S2, GHRH analogues); may fall under the German AntiDopG.

Sources

Note: We deliberately do not list any doses here. For approved medicines, your doctor sets the dose; for unapproved substances there is no reliable information.